Results of a Multicenter Trial in the Treatment of Advanced Renal Cell Carcinoma with a Combination of Recombinant Interferon Alpha-2 a and Vinblastine

1989 ◽  
pp. 292-299
Author(s):  
D. Schuster ◽  
G. Schneider ◽  
N. Ade ◽  
M. E. Heim
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Multicenter Trial ◽  
Advanced Renal Cell Carcinoma ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

Recombinant interferon alpha-2 in advanced renal cell carcinoma

1992 ◽  
Vol 59 (3) ◽  
pp. 74-77 ◽  
Author(s):  
A. Cozzoli ◽  
S. Cosciani Cunico
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Residual Disease ◽  
Advanced Renal Cell Carcinoma ◽  
Complete Regression ◽  
Recombinant Interferon ◽  
Retroperitoneal Node ◽  
Recombinant Interferon Alpha

From January 1985 to December 1987, 26 patients (20 men, 6 women, median age 62 years, range 26–76 years) with advanced renal cell carcinoma were included in the study. In 8 cases (6 patients no surgery, 2 patients with retroperitoneal node-residual disease after nephrectomy) metastases were identified at initial diagnosis, and in the remaining 18 the occurrence of metastases was delayed by a mean disease-free interval of 12 months after radical nephrectomy. Recombinant interferon alpha-2 was administered subcutaneously at a dose of 9 milion IU three times a week for a period of at least six months. Informed consent was obtained from all patients before starting therapy. No patients achieved complete regression of tumors; two cases showed a partial response (one relapsed six months later, while in the other response continues at 38 months after discontinuation of therapy); 10 patients showed stabilization of disease for 6–10 months and in 14 the disease progressed immediately. In our experience immunotherapy with recombinant interferon alpha-2 did not significantly change the natural history of renal cell carcinoma.

Phase II Study of Recombinant Interferon Alpha-2A and Vinblastine in Advanced Renal Cell Carcinoma

1989 ◽  
Vol 142 (2 Part 1) ◽  
pp. 253-256 ◽  
Author(s):  
Jan H. Schornagel ◽  
Jaap Verweij ◽  
Wim W. Ten Bokkel Huinink ◽  
Jan G.M. Klijn ◽  
Pieter H.M. De Mulder ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Advanced Renal Cell Carcinoma ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma

2009 ◽  
Vol 48 (1) ◽  
pp. 154-156 ◽  
Author(s):  
Patricia M. M. B. Soetekouw ◽  
M. Koopman ◽  
David Burger ◽  
Vivianne C. G. Tjan-Heijnen ◽  
P. H. M. De Mulder
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Severe Hyponatremia ◽  
Interferon Alpha Therapy ◽  
Alpha Therapy
Sign in / Sign up

Export Citation Format

Share Document